ArticleVaccine2017
Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model.
Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 55 citations in OpenAlex.
- Extracellular vesicles as new-age vaccine carriers: a focused account on viral diseases.Frontiers in immunology · 2026Review
- RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2.Journal of nanobiotechnology · 2025Article
- Immune Responses Elicited by Outer Membrane Vesicles of Gram-Negative Bacteria: Important Players in Vaccine Development.Life (Basel, Switzerland) · 2024Review
- Delivery ofmSphere · 2024Article
- Harnessing Bacterial Extracellular Vesicle Immune Effects for Cancer Therapy.Pathogens & immunity · 2024Review
- Interactions between extracellular vesicles and microbiome in human diseases: New therapeutic opportunities.iMeta · 2023Review
- Targeting Capabilities of Native and Bioengineered Extracellular Vesicles for Drug Delivery.Bioengineering (Basel, Switzerland) · 2022Review
- Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer.Advanced drug delivery reviews · 2022Review
- Inhibitors of Bacterial Extracellular Vesicles.Frontiers in microbiology · 2022Review
- Biomimetic Nanoparticles Coated with Bacterial Outer Membrane Vesicles as a New-Generation Platform for Biomedical Applications.Pharmaceutics · 2021Review
- Engineered Remolding and Application of Bacterial Membrane Vesicles.Frontiers in microbiology · 2021Review
- Exosome-Based Vaccines: History, Current State, and Clinical Trials.Frontiers in immunology · 2021Review
- OMV Vaccines and the Role of TLR Agonists in Immune Response.International journal of molecular sciences · 2020Review
- TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection.Frontiers in immunology · 2020Review
- Role of Extracellular Vesicles in Influenza Virus Infection.Frontiers in cellular and infection microbiology · 2020Review
- Truncated Core/NS3 Fusion Protein of HCV Adjuvanted with Outer Membrane Vesicles of Neisseria meningitidis Serogroup B: Potent Inducer of the Murine Immune SystemIranian biomedical journal · 2019Article
- Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections.Frontiers in immunology · 2019Review
- Bacterial Outer Membrane Vesicles Provide Broad-Spectrum Protection against Influenza Virus Infection via Recruitment and Activation of Macrophages.Journal of innate immunity · 2019Article
- The Therapeutic Benefit of Bacterial Membrane Vesicles.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza is an acute respiratory disease and a major health problem worldwide. Since mucosal immunity plays a critical role in protection against influenza virus infection, mucosal immunization is considered a promising vaccination route. However, except for live-attenuated vaccines, there are no effective killed or recombinant mucosal influenza vaccines to date. Outer membrane vesicles (OMVs) are nano-sized vesicles produced by gram-negative bacteria, and contain various bacterial components capable of stimulating the immune system of the host. We generated an OMV with low endotoxicity (fmOMV) by modifying the structure of the lipid A moiety of lipopolysaccharide and investigated its effect as an intranasal vaccine adjuvant in an influenza vaccine model. In this model, fmOMV exhibited reduced toll-like receptor 4-stimulating activity and attenuated endotoxicity compared to that of native OMV. Intranasal injection of the vaccine antigen with fmOMV significantly increased systemic antibody and T cell responses, mucosal IgA levels, and the frequency of lung-resident influenza-specific T cells. In addition, the number of antigen-bearing CD103
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.